Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous and Allogeneic MSCs in MSA
NCT04876326Unknown
- Sponsor
- Universitas Indonesia
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous adipose-derived mesenchymal stromal cells, allogeneic umbilical cord-derived mesenchymal stem cells and AT-MSC secretome in multiple system atrophy (MSA) (3 arms), sponsored by Universitas Indonesia. Primary endpoints: Changes of Clinical Evaluation at 12 months, Changes of structures improvement of the eyes at 12 months and 2 more. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stromal cellsallogeneic umbilical cord-derived mesenchymal stem cellsAT-MSC secretome
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04876326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876326.